Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Veterans With Alcohol Use Disorder (CRAVE)
NCT07218354Phase 3Recruiting
- Sponsor
- VA Office of Research & Development
- Start
- Jul 2026
- Primary completion
- Mar 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in alcohol use disorder (AUD) comparing Semaglutide with Placebo (2 arms). Primary endpoint: Two-level reduction in the World Health Organization risk drinking level at 24 weeks. Started Jul 2026; status: recruiting.
02
Drugs
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT07218354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07218354.